Brought to you by 
PerkinElmer purchases ViaCell for $283mm
23 Oct 2007
Executive Summary
PerkinElmer will buy umbilical cord blood banking company ViaCell in a tender offer valued at about $283mm. PerkinElmer will pay $7.25 for each outstanding ViaCell share, a 54% premium to the pre-announcement market average. (Immediately following the after-hours news release of the deal, ViaCell's stock climbed as much as 50% higher than its previous close.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PerkinElmer purchases ViaCell for $283mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice